Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2019-12-19 Major Shareholding Noti…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 5 pages 139.9KB
Major Shareholding Notification Classification · 100% confidence The document is a formal notice under the Corporations Act 2001 Section 671B titled 'Notice of ceasing to be a substantial holder.' It details changes in substantial shareholding interests, including dates, parties involved, and associations. The content is regulatory in nature, reporting changes in ownership stakes rather than financial performance, management changes, or other report types. It is not an annual report, earnings release, or any financial statement. It is a notification related to major shareholding changes, specifically the cessation of substantial holding status. Therefore, the document fits the category of Major Shareholding Notification (MRQ). The document length and detail support a confident classification.
2019-12-19 English
Boehringer discontinues development of BI 1467335 for NASH 2 pages 124.8KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the discontinuation of development of a specific drug candidate (BI 1467335) for NASH by Boehringer Ingelheim and Pharmaxis Ltd. It provides details about the clinical trial results, reasons for discontinuation, and ongoing related studies. The document is not a financial report, regulatory filing, or detailed management discussion. It is a corporate announcement about a research and development update, specifically a product development discontinuation. This type of document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories such as earnings releases, annual reports, or management reports. The document length (6783 characters) and content confirm it is not a brief report publication announcement or a full financial report. Therefore, the appropriate classification is RNS with high confidence.
2019-12-17 English
Pharmaxis Business Plan Update 2 pages 115.9KB
Capital/Financing Update Classification · 95% confidence The document is a media release dated 18 December 2019 from Pharmaxis Ltd providing an update on its business plan, drug development pipeline, partnering discussions, and clinical development milestones. It discusses recent events such as Boehringer Ingelheim's decision not to progress a drug study, cash position, milestone payments, and future plans. The document does not contain financial statements, detailed financial performance data, or regulatory filings. It is an operational update and business plan progress announcement rather than a formal financial report or regulatory filing. It is not an earnings release, annual or interim report, audit report, or any other formal report type. The content fits best under Capital/Financing Update (CAP) as it discusses partnering, milestone payments, and funding related to drug development programs and business plans.
2019-12-17 English
Investor Conference Call 2 pages 108.0KB
Call Transcript Classification · 85% confidence The document is a media release announcing an investor conference call scheduled for 18 December 2019. It provides details on how to access the call, including dial-in numbers and a webcast link. The content focuses on the announcement of Boehringer Ingelheim's development plans for a drug acquired from Pharmaxis and the lifting of a trading halt. There are no financial statements, detailed financial analysis, or substantive financial data presented in the text. The document is essentially an announcement of an upcoming event (conference call) rather than the transcript of the call itself or a financial report. Therefore, the document fits best into the category of a Call Transcript (CT) only if it contained the full transcript, which it does not. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or regulatory filing. Given the nature of the document as a media release announcing a conference call, the most appropriate classification is Call Transcript (CT) because it is directly related to a conference call event, but since it is only an announcement and not the transcript, the fallback is Regulatory Filings (RNS). However, since the document is specifically about the conference call and includes detailed call access information, it aligns best with Call Transcript (CT) category as a preparatory document for the call. Confidence is high due to clear indicators of a conference call announcement and absence of financial data or other report types.
2019-12-16 English
Trading Halt 2 pages 105.1KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Pharmaxis Ltd regarding a trading halt requested under ASX Listing Rule 7.1. It explains the reason for the halt, which is to manage continuous disclosure obligations related to advice received about a drug development plan. The document is short (2432 characters) and does not contain any financial data, report content, or detailed analysis. It is an announcement about a trading halt, not a financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance documents that do not fit other specific categories.
2019-12-15 English
Investor Presentation 18 pages 991.1KB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's product pipeline, management team, financial position, and upcoming catalysts. It includes forward-looking statements, descriptions of drug development stages, and strategic partnerships. The content is typical of a presentation aimed at investors to provide an overview of the company's business, strategy, and financial outlook. There are no indications that this is a regulatory filing, earnings release, or annual report. The length (15,000 characters) and detailed content support classification as an Investor Presentation rather than a brief summary or announcement.
2019-11-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.